Compare Neurocrine Biosciences Inc (NBIX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

TCPC trades at $3.92, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a high P/S ratio of 70.7 but a discounted P/B of 0.59.

The outlook is mixed: strategic actions and dividend yield near 8.7% offer value, but declining revenue, negative ROE/ROA, and class-action lawsuits pose significant risks. Analyst consensus is cautious with 30.8% buy ratings, suggesting limited upside without fundamental improvement.